This drug company just made a killing on the bourses. Know why
Advertisement
Advertisement
Shares off midcap drugs major Marksans said on June 30th that it had purchased 100 percent of
Marksans will be able to expand its presence in the fast growing US generics space after this purchase, the company said in a statement.
Meanwhile, its stock was trading at 84.60 rupees, up 14.1 rupees with 2.3 crore shares changing hands on the NSE. The stock closed at 63.80 rupees on June 30.
Marksans reported a net profit of 12.3 crore rupees on sales of 94 crore rupees for the last quarter of March 2015 compared with an after tax profit of 5.3 crore rupees and sales of 84.3 crore rupees in the same quarter a year ago.
Advertisement
(image credits: marksanspharma)
Advertisement
- Global stocks rally even as Sensex, Nifty fall sharply on Friday
- In second consecutive week of decline, forex kitty drops $2.28 bn to $640.33 bn
- SBI Life Q4 profit rises 4% to ₹811 crore
- IMD predicts severe heatwave conditions over East, South Peninsular India for next five days
- COVID lockdown-related school disruptions will continue to worsen students’ exam results into the 2030s: study
- JNK India IPO allotment date
- JioCinema New Plans
- Realme Narzo 70 Launched
- Apple Let Loose event
- Elon Musk Apology
- RIL cash flows
- Charlie Munger
- Feedbank IPO allotment
- Tata IPO allotment
- Most generous retirement plans
- Broadcom lays off
- Cibil Score vs Cibil Report
- Birla and Bajaj in top Richest
- Nestle Sept 2023 report
- India Equity Market